 David Brown
Concepts (565)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Reperfusion Injury | 21 | 2021 | 135 | 4.570 |
Why?
| | Mitochondria, Heart | 11 | 2020 | 102 | 1.930 |
Why?
| | Neurons | 10 | 2020 | 1590 | 1.530 |
Why?
| | KCNQ2 Potassium Channel | 4 | 2013 | 10 | 1.380 |
Why?
| | Oligopeptides | 7 | 2024 | 271 | 1.320 |
Why?
| | Action Potentials | 11 | 2019 | 493 | 1.290 |
Why?
| | Physical Conditioning, Animal | 8 | 2013 | 257 | 1.210 |
Why?
| | Locomotion | 5 | 2015 | 106 | 1.180 |
Why?
| | Myocardial Infarction | 10 | 2021 | 1046 | 1.170 |
Why?
| | Mitochondria | 7 | 2021 | 948 | 1.070 |
Why?
| | Myocardium | 12 | 2020 | 1002 | 1.060 |
Why?
| | Adaptation, Physiological | 6 | 2011 | 553 | 0.990 |
Why?
| | Rats, Sprague-Dawley | 27 | 2020 | 2486 | 0.970 |
Why?
| | Ion Channels | 2 | 2020 | 133 | 0.950 |
Why?
| | Rats | 33 | 2021 | 5647 | 0.940 |
Why?
| | Reactive Oxygen Species | 6 | 2021 | 622 | 0.940 |
Why?
| | Energy Metabolism | 5 | 2021 | 922 | 0.940 |
Why?
| | Potassium Channel Blockers | 6 | 2013 | 37 | 0.840 |
Why?
| | Transducers | 3 | 2012 | 27 | 0.810 |
Why?
| | Robotics | 1 | 2024 | 94 | 0.810 |
Why?
| | Acoustics | 3 | 2012 | 42 | 0.810 |
Why?
| | Potassium Channels | 5 | 2010 | 151 | 0.790 |
Why?
| | Receptors, Purinergic P2 | 3 | 2010 | 23 | 0.790 |
Why?
| | Reperfusion Injury | 5 | 2014 | 279 | 0.790 |
Why?
| | Arrhythmias, Cardiac | 4 | 2016 | 333 | 0.790 |
Why?
| | Calcium | 13 | 2019 | 1199 | 0.760 |
Why?
| | KCNQ Potassium Channels | 3 | 2019 | 4 | 0.750 |
Why?
| | Walking | 3 | 2024 | 529 | 0.740 |
Why?
| | Animals | 56 | 2021 | 36940 | 0.730 |
Why?
| | Exercise Test | 6 | 2024 | 625 | 0.720 |
Why?
| | Stroke | 6 | 2015 | 1120 | 0.720 |
Why?
| | NADH Dehydrogenase | 1 | 2021 | 19 | 0.710 |
Why?
| | Pyramidal Cells | 3 | 2019 | 74 | 0.670 |
Why?
| | Myocytes, Cardiac | 5 | 2016 | 526 | 0.660 |
Why?
| | Pharmacology | 1 | 2020 | 9 | 0.660 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 4 | 2007 | 32 | 0.640 |
Why?
| | Muscle, Skeletal | 8 | 2011 | 1724 | 0.640 |
Why?
| | Amino Acids, Dicarboxylic | 1 | 2019 | 8 | 0.630 |
Why?
| | Prolyl-Hydroxylase Inhibitors | 1 | 2019 | 5 | 0.620 |
Why?
| | Mitochondrial Membrane Transport Proteins | 3 | 2017 | 43 | 0.620 |
Why?
| | Brain Injuries | 1 | 2024 | 494 | 0.610 |
Why?
| | Psychomotor Performance | 3 | 2011 | 309 | 0.610 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2011 | 68 | 0.610 |
Why?
| | Mitochondrial Membranes | 3 | 2020 | 39 | 0.600 |
Why?
| | Glutathione | 4 | 2016 | 356 | 0.600 |
Why?
| | Potassium Channels, Inwardly Rectifying | 4 | 2006 | 38 | 0.580 |
Why?
| | Exercise Therapy | 3 | 2016 | 443 | 0.580 |
Why?
| | Surgical Flaps | 1 | 2019 | 130 | 0.560 |
Why?
| | Mitochondria, Liver | 2 | 2017 | 73 | 0.550 |
Why?
| | Cardiolipins | 6 | 2020 | 85 | 0.530 |
Why?
| | KCNQ1 Potassium Channel | 2 | 2018 | 7 | 0.520 |
Why?
| | Burns | 2 | 2023 | 325 | 0.520 |
Why?
| | Propranolol | 1 | 2016 | 50 | 0.500 |
Why?
| | Glutathione Reductase | 2 | 2013 | 25 | 0.500 |
Why?
| | Patch-Clamp Techniques | 9 | 2013 | 286 | 0.490 |
Why?
| | Sarcolemma | 2 | 2006 | 43 | 0.490 |
Why?
| | Guinea Pigs | 3 | 2013 | 158 | 0.480 |
Why?
| | Stroke Rehabilitation | 5 | 2011 | 42 | 0.470 |
Why?
| | Adenosine Triphosphate | 4 | 2021 | 491 | 0.450 |
Why?
| | Nandrolone | 1 | 2014 | 3 | 0.440 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2014 | 10 | 0.440 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2014 | 25 | 0.440 |
Why?
| | Mitochondrial Myopathies | 2 | 2024 | 9 | 0.440 |
Why?
| | Postural Balance | 2 | 2021 | 215 | 0.440 |
Why?
| | Heart | 7 | 2020 | 655 | 0.440 |
Why?
| | Skin | 3 | 2023 | 752 | 0.430 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 38 | 0.430 |
Why?
| | Physical Exertion | 3 | 2016 | 215 | 0.430 |
Why?
| | Pain Management | 2 | 2010 | 352 | 0.420 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2014 | 54 | 0.420 |
Why?
| | Bradykinin | 3 | 2010 | 46 | 0.410 |
Why?
| | Apoptosis | 3 | 2021 | 2553 | 0.400 |
Why?
| | Leg | 3 | 2011 | 236 | 0.400 |
Why?
| | Membrane Lipids | 1 | 2013 | 91 | 0.400 |
Why?
| | Sound | 1 | 2012 | 48 | 0.390 |
Why?
| | NADPH Oxidases | 1 | 2013 | 113 | 0.390 |
Why?
| | Receptors, Muscarinic | 4 | 2007 | 19 | 0.380 |
Why?
| | Male | 43 | 2024 | 67762 | 0.380 |
Why?
| | In Vitro Techniques | 7 | 2016 | 1092 | 0.380 |
Why?
| | Time Factors | 10 | 2016 | 6828 | 0.380 |
Why?
| | Extremities | 2 | 2011 | 131 | 0.380 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2011 | 6 | 0.380 |
Why?
| | Cardiotonic Agents | 3 | 2020 | 124 | 0.370 |
Why?
| | Keratinocytes | 1 | 2013 | 249 | 0.370 |
Why?
| | Nerve Tissue Proteins | 2 | 2013 | 596 | 0.370 |
Why?
| | Pain | 2 | 2010 | 756 | 0.360 |
Why?
| | Water | 2 | 2012 | 460 | 0.360 |
Why?
| | Myocardial Ischemia | 5 | 2020 | 263 | 0.360 |
Why?
| | Anesthetics, Combined | 1 | 2011 | 9 | 0.360 |
Why?
| | Animals, Laboratory | 1 | 2011 | 18 | 0.360 |
Why?
| | Xylazine | 1 | 2011 | 14 | 0.360 |
Why?
| | Up-Regulation | 5 | 2018 | 843 | 0.350 |
Why?
| | Motor Activity | 3 | 2011 | 718 | 0.350 |
Why?
| | Synapses | 3 | 2019 | 427 | 0.350 |
Why?
| | Th17 Cells | 1 | 2011 | 108 | 0.340 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 195 | 0.340 |
Why?
| | Axons | 2 | 2011 | 198 | 0.340 |
Why?
| | Anesthetics | 1 | 2011 | 81 | 0.340 |
Why?
| | Ketamine | 1 | 2011 | 94 | 0.330 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2010 | 40 | 0.330 |
Why?
| | Biomechanical Phenomena | 4 | 2024 | 810 | 0.320 |
Why?
| | Cytoskeletal Proteins | 1 | 2010 | 158 | 0.320 |
Why?
| | Cells, Cultured | 10 | 2018 | 4193 | 0.310 |
Why?
| | Myocardial Contraction | 3 | 2020 | 341 | 0.300 |
Why?
| | Absorbable Implants | 1 | 2009 | 35 | 0.300 |
Why?
| | Physical Therapists | 2 | 2021 | 62 | 0.300 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2011 | 385 | 0.300 |
Why?
| | Arterial Occlusive Diseases | 1 | 2009 | 83 | 0.290 |
Why?
| | Convulsants | 1 | 2008 | 8 | 0.290 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2006 | 137 | 0.290 |
Why?
| | Dendritic Cells | 1 | 2011 | 483 | 0.290 |
Why?
| | Benzodiazepinones | 1 | 2008 | 17 | 0.290 |
Why?
| | Blood Vessel Prosthesis | 1 | 2009 | 127 | 0.280 |
Why?
| | Genetic Diseases, Inborn | 1 | 2008 | 44 | 0.280 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 179 | 0.280 |
Why?
| | Superior Cervical Ganglion | 4 | 2013 | 5 | 0.280 |
Why?
| | Exercise | 2 | 2011 | 2057 | 0.270 |
Why?
| | Electromyography | 5 | 2015 | 400 | 0.270 |
Why?
| | KCNQ3 Potassium Channel | 1 | 2007 | 3 | 0.270 |
Why?
| | Calcium Signaling | 2 | 2012 | 249 | 0.270 |
Why?
| | Hippocalcin | 1 | 2007 | 1 | 0.270 |
Why?
| | Nerve Degeneration | 1 | 2007 | 46 | 0.270 |
Why?
| | Humans | 42 | 2024 | 137585 | 0.270 |
Why?
| | Coronary Circulation | 3 | 2021 | 143 | 0.260 |
Why?
| | Phenylenediamines | 3 | 2013 | 10 | 0.260 |
Why?
| | Membrane Proteins | 1 | 2013 | 1164 | 0.260 |
Why?
| | Calcium Channels | 2 | 2010 | 159 | 0.260 |
Why?
| | Female | 32 | 2024 | 73304 | 0.250 |
Why?
| | Carbamates | 3 | 2013 | 50 | 0.250 |
Why?
| | Vibration | 3 | 2012 | 72 | 0.250 |
Why?
| | Hydrolases | 1 | 2006 | 48 | 0.250 |
Why?
| | Hydroxamic Acids | 1 | 2006 | 89 | 0.250 |
Why?
| | Prosencephalon | 1 | 2006 | 48 | 0.250 |
Why?
| | Phospholipids | 2 | 2017 | 223 | 0.240 |
Why?
| | Stents | 2 | 2013 | 527 | 0.240 |
Why?
| | Posture | 2 | 2021 | 185 | 0.240 |
Why?
| | Acetylcholine | 1 | 2006 | 185 | 0.230 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2019 | 124 | 0.230 |
Why?
| | Organometallic Compounds | 1 | 2006 | 111 | 0.230 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2007 | 220 | 0.230 |
Why?
| | Oxidation-Reduction | 4 | 2013 | 1060 | 0.230 |
Why?
| | Bicycling | 2 | 2005 | 114 | 0.230 |
Why?
| | Sodium | 3 | 2020 | 217 | 0.220 |
Why?
| | Parotid Gland | 1 | 2004 | 23 | 0.220 |
Why?
| | Linoleic Acid | 2 | 2017 | 43 | 0.220 |
Why?
| | KATP Channels | 3 | 2011 | 20 | 0.220 |
Why?
| | Protein Structure, Tertiary | 2 | 2008 | 861 | 0.220 |
Why?
| | Stress, Physiological | 1 | 2007 | 443 | 0.220 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1050 | 0.210 |
Why?
| | Glutamic Acid | 1 | 2006 | 246 | 0.210 |
Why?
| | Cyclic AMP | 1 | 2004 | 234 | 0.210 |
Why?
| | Tissue Engineering | 1 | 2007 | 423 | 0.200 |
Why?
| | Models, Animal | 3 | 2011 | 384 | 0.200 |
Why?
| | Sex Characteristics | 2 | 2006 | 762 | 0.200 |
Why?
| | Cicatrix | 1 | 2023 | 64 | 0.200 |
Why?
| | Zinc | 1 | 2006 | 297 | 0.200 |
Why?
| | Neurons, Afferent | 1 | 2003 | 97 | 0.200 |
Why?
| | Skin Transplantation | 2 | 2023 | 85 | 0.200 |
Why?
| | Middle Aged | 12 | 2024 | 33479 | 0.200 |
Why?
| | Physical Examination | 2 | 2021 | 241 | 0.200 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 840 | 0.200 |
Why?
| | Receptors, Bradykinin | 1 | 2002 | 5 | 0.190 |
Why?
| | Inositol 1,4,5-Trisphosphate | 1 | 2002 | 21 | 0.190 |
Why?
| | Anaphylaxis | 1 | 2023 | 105 | 0.190 |
Why?
| | Movement | 2 | 2021 | 278 | 0.190 |
Why?
| | Mutation | 3 | 2013 | 3958 | 0.180 |
Why?
| | Aged | 10 | 2024 | 23961 | 0.180 |
Why?
| | Oxygen Consumption | 3 | 2021 | 696 | 0.180 |
Why?
| | Equipment Design | 3 | 2012 | 522 | 0.180 |
Why?
| | Body Weight | 4 | 2013 | 985 | 0.180 |
Why?
| | Coronary Occlusion | 1 | 2021 | 19 | 0.180 |
Why?
| | Genotype | 2 | 2024 | 1916 | 0.170 |
Why?
| | Leigh Disease | 1 | 2020 | 21 | 0.170 |
Why?
| | Rhabdomyolysis | 1 | 2020 | 21 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4295 | 0.170 |
Why?
| | Titanium | 2 | 2019 | 82 | 0.170 |
Why?
| | Acidosis, Lactic | 1 | 2020 | 46 | 0.170 |
Why?
| | Gene Expression | 3 | 2015 | 1502 | 0.170 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 220 | 0.170 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2019 | 72 | 0.160 |
Why?
| | Isolated Heart Preparation | 2 | 2017 | 6 | 0.160 |
Why?
| | CRISPR-Cas Systems | 1 | 2021 | 125 | 0.160 |
Why?
| | Rabbits | 2 | 2013 | 794 | 0.160 |
Why?
| | Neurotransmitter Agents | 1 | 2020 | 81 | 0.160 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2019 | 11 | 0.160 |
Why?
| | Rats, Hairless | 1 | 2019 | 1 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2008 | 382 | 0.160 |
Why?
| | Ischemia | 2 | 2021 | 409 | 0.160 |
Why?
| | Anthracenes | 2 | 2013 | 31 | 0.150 |
Why?
| | Mitochondrial Diseases | 1 | 2020 | 91 | 0.150 |
Why?
| | Glycolysis | 1 | 2021 | 321 | 0.150 |
Why?
| | RNA, Messenger | 5 | 2018 | 2833 | 0.150 |
Why?
| | Cell Membrane | 3 | 2008 | 738 | 0.150 |
Why?
| | Nasal Septum | 1 | 2019 | 25 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2013 | 2057 | 0.150 |
Why?
| | Dendrites | 2 | 2011 | 105 | 0.150 |
Why?
| | Nasal Obstruction | 1 | 2019 | 27 | 0.150 |
Why?
| | Ischemic Preconditioning | 1 | 2019 | 41 | 0.150 |
Why?
| | Unilamellar Liposomes | 1 | 2018 | 8 | 0.150 |
Why?
| | Proteolipids | 1 | 2018 | 31 | 0.150 |
Why?
| | Preoperative Period | 1 | 2019 | 129 | 0.150 |
Why?
| | Rhinoplasty | 1 | 2019 | 29 | 0.150 |
Why?
| | Membrane Microdomains | 1 | 2018 | 32 | 0.150 |
Why?
| | Cleft Lip | 1 | 2019 | 52 | 0.150 |
Why?
| | Models, Anatomic | 1 | 2019 | 93 | 0.150 |
Why?
| | Coronary Artery Disease | 2 | 2021 | 698 | 0.150 |
Why?
| | Hydrolysis | 2 | 2010 | 177 | 0.150 |
Why?
| | HEK293 Cells | 1 | 2021 | 730 | 0.150 |
Why?
| | Ventricular Function, Left | 4 | 2016 | 534 | 0.150 |
Why?
| | Presynaptic Terminals | 1 | 2019 | 88 | 0.140 |
Why?
| | Mice | 8 | 2019 | 17787 | 0.140 |
Why?
| | Cleft Palate | 1 | 2019 | 68 | 0.140 |
Why?
| | Receptors, Purinergic P2Y1 | 2 | 2010 | 7 | 0.140 |
Why?
| | Necrosis | 1 | 2019 | 246 | 0.140 |
Why?
| | Citrate (si)-Synthase | 3 | 2009 | 60 | 0.140 |
Why?
| | Movement Disorders | 1 | 2018 | 58 | 0.140 |
Why?
| | Vitiligo | 1 | 2017 | 42 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 250 | 0.140 |
Why?
| | Adult | 9 | 2024 | 37929 | 0.130 |
Why?
| | Docosahexaenoic Acids | 1 | 2017 | 84 | 0.130 |
Why?
| | Receptor, Bradykinin B2 | 2 | 2010 | 4 | 0.130 |
Why?
| | Ganglia, Spinal | 2 | 2010 | 77 | 0.130 |
Why?
| | Oxidative Stress | 2 | 2016 | 1317 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 976 | 0.130 |
Why?
| | Synaptic Transmission | 1 | 2019 | 289 | 0.130 |
Why?
| | Physical Therapy Modalities | 2 | 2018 | 308 | 0.130 |
Why?
| | Transfection | 3 | 2010 | 945 | 0.130 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 40 | 0.130 |
Why?
| | Signal Transduction | 4 | 2019 | 5079 | 0.120 |
Why?
| | Inflammation | 1 | 2007 | 2837 | 0.120 |
Why?
| | Bradycardia | 1 | 2016 | 55 | 0.120 |
Why?
| | Diet, High-Fat | 1 | 2017 | 247 | 0.120 |
Why?
| | Kynurenine 3-Monooxygenase | 1 | 2015 | 5 | 0.120 |
Why?
| | CHO Cells | 2 | 2007 | 161 | 0.120 |
Why?
| | Sodium-Calcium Exchanger | 3 | 2020 | 16 | 0.120 |
Why?
| | Type C Phospholipases | 3 | 2005 | 74 | 0.120 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 56 | 0.120 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2018 | 248 | 0.120 |
Why?
| | Cricetinae | 2 | 2007 | 289 | 0.120 |
Why?
| | Hypotension | 1 | 2016 | 122 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2019 | 579 | 0.110 |
Why?
| | Running | 2 | 2016 | 230 | 0.110 |
Why?
| | Particulate Matter | 1 | 2017 | 315 | 0.110 |
Why?
| | Benzamides | 2 | 2006 | 216 | 0.110 |
Why?
| | Membrane Potentials | 2 | 2018 | 284 | 0.110 |
Why?
| | Motion | 2 | 2012 | 99 | 0.110 |
Why?
| | Mice, Inbred C57BL | 4 | 2018 | 5757 | 0.110 |
Why?
| | Kynurenine | 1 | 2015 | 114 | 0.110 |
Why?
| | Neural Inhibition | 2 | 2006 | 169 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 283 | 0.110 |
Why?
| | Disease Susceptibility | 3 | 2019 | 347 | 0.110 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2020 | 156 | 0.110 |
Why?
| | Tetraethylammonium | 1 | 2013 | 16 | 0.110 |
Why?
| | Estrous Cycle | 1 | 2013 | 20 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2013 | 88 | 0.110 |
Why?
| | Coronary Vessels | 2 | 2016 | 248 | 0.110 |
Why?
| | Rodent Diseases | 1 | 2013 | 28 | 0.100 |
Why?
| | Monoterpenes | 1 | 2013 | 16 | 0.100 |
Why?
| | No-Reflow Phenomenon | 1 | 2013 | 7 | 0.100 |
Why?
| | Computer Simulation | 2 | 2008 | 978 | 0.100 |
Why?
| | Neurodegenerative Diseases | 1 | 2015 | 135 | 0.100 |
Why?
| | Paresis | 2 | 2011 | 30 | 0.100 |
Why?
| | Kinetics | 2 | 2010 | 1670 | 0.100 |
Why?
| | TRPV Cation Channels | 1 | 2013 | 40 | 0.100 |
Why?
| | Ceramics | 1 | 2012 | 22 | 0.100 |
Why?
| | GTP-Binding Proteins | 2 | 2004 | 161 | 0.100 |
Why?
| | Appetite | 1 | 2013 | 69 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 558 | 0.100 |
Why?
| | Mitochondrial ADP, ATP Translocases | 1 | 2012 | 2 | 0.100 |
Why?
| | Nanotubes, Carbon | 1 | 2012 | 47 | 0.100 |
Why?
| | Protein Isoforms | 2 | 2005 | 404 | 0.100 |
Why?
| | Glutathione Disulfide | 1 | 2012 | 33 | 0.100 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2011 | 7 | 0.090 |
Why?
| | Minocycline | 1 | 2012 | 27 | 0.090 |
Why?
| | Vasoconstrictor Agents | 1 | 2012 | 139 | 0.090 |
Why?
| | Protein Kinase C | 2 | 2004 | 261 | 0.090 |
Why?
| | Superoxide Dismutase | 2 | 2005 | 346 | 0.090 |
Why?
| | Heart Rate | 1 | 2016 | 822 | 0.090 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2012 | 145 | 0.090 |
Why?
| | Pressure | 1 | 2012 | 225 | 0.090 |
Why?
| | Macrophages | 1 | 2019 | 1547 | 0.090 |
Why?
| | Glutathione Peroxidase | 1 | 2011 | 43 | 0.090 |
Why?
| | Permeability | 1 | 2012 | 161 | 0.090 |
Why?
| | Models, Biological | 2 | 2010 | 1783 | 0.090 |
Why?
| | Electricity | 1 | 2011 | 23 | 0.090 |
Why?
| | Quality of Life | 1 | 2023 | 2892 | 0.090 |
Why?
| | Calcium Channel Blockers | 1 | 2012 | 167 | 0.090 |
Why?
| | Receptor, Metabotropic Glutamate 5 | 1 | 2010 | 5 | 0.090 |
Why?
| | Cyclosporine | 1 | 2012 | 268 | 0.090 |
Why?
| | Peptides | 1 | 2016 | 985 | 0.090 |
Why?
| | Tissue and Organ Harvesting | 1 | 2011 | 70 | 0.090 |
Why?
| | Cardiac Glycosides | 1 | 2010 | 1 | 0.090 |
Why?
| | Calcium Channels, N-Type | 1 | 2010 | 10 | 0.090 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 2010 | 24 | 0.090 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 20 | 0.080 |
Why?
| | Hemodynamics | 2 | 2013 | 1113 | 0.080 |
Why?
| | Muscarinic Agonists | 2 | 2007 | 16 | 0.080 |
Why?
| | Nociceptors | 1 | 2010 | 38 | 0.080 |
Why?
| | Ions | 1 | 2010 | 70 | 0.080 |
Why?
| | Mice, Transgenic | 2 | 2013 | 2167 | 0.080 |
Why?
| | Bone Nails | 1 | 2010 | 62 | 0.080 |
Why?
| | Models, Theoretical | 2 | 2011 | 578 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2011 | 302 | 0.080 |
Why?
| | Astrocytes | 1 | 2011 | 210 | 0.080 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2009 | 17 | 0.080 |
Why?
| | Oxygen | 2 | 2021 | 931 | 0.080 |
Why?
| | Sulfhydryl Compounds | 1 | 2011 | 189 | 0.080 |
Why?
| | Femoral Fractures | 1 | 2010 | 76 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2013 | 1477 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2011 | 474 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2023 | 15657 | 0.080 |
Why?
| | Ankyrins | 1 | 2008 | 13 | 0.070 |
Why?
| | Recovery of Function | 2 | 2009 | 653 | 0.070 |
Why?
| | Rats, Inbred Strains | 1 | 2008 | 362 | 0.070 |
Why?
| | G Protein-Coupled Inwardly-Rectifying Potassium Channels | 2 | 2005 | 10 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2013 | 3015 | 0.070 |
Why?
| | Transcortin | 1 | 2007 | 16 | 0.070 |
Why?
| | Basal Ganglia | 1 | 2008 | 56 | 0.070 |
Why?
| | Phenolsulfonphthalein | 1 | 2007 | 1 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 629 | 0.070 |
Why?
| | Animals, Newborn | 2 | 2007 | 844 | 0.070 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2007 | 32 | 0.070 |
Why?
| | Hepatocyte Growth Factor | 1 | 2007 | 35 | 0.070 |
Why?
| | Freund's Adjuvant | 1 | 2007 | 18 | 0.070 |
Why?
| | Muscarine | 1 | 2007 | 3 | 0.070 |
Why?
| | Bicarbonates | 1 | 2007 | 44 | 0.070 |
Why?
| | Adrenal Glands | 1 | 2007 | 78 | 0.070 |
Why?
| | Thapsigargin | 1 | 2007 | 20 | 0.070 |
Why?
| | Finite Element Analysis | 1 | 2007 | 75 | 0.070 |
Why?
| | Fluoresceins | 1 | 2007 | 47 | 0.070 |
Why?
| | Chemokine CXCL12 | 1 | 2007 | 81 | 0.070 |
Why?
| | Ranidae | 1 | 2007 | 14 | 0.070 |
Why?
| | Coloring Agents | 1 | 2007 | 87 | 0.070 |
Why?
| | Protein Subunits | 1 | 2008 | 239 | 0.070 |
Why?
| | Hypertrophy | 1 | 2007 | 133 | 0.070 |
Why?
| | Diffusion | 1 | 2007 | 116 | 0.070 |
Why?
| | Phosphatidylethanolamines | 2 | 2017 | 77 | 0.070 |
Why?
| | Cricetulus | 1 | 2007 | 109 | 0.070 |
Why?
| | Atrophy | 1 | 2007 | 184 | 0.070 |
Why?
| | Hydrogen Peroxide | 2 | 2020 | 328 | 0.070 |
Why?
| | Cell Respiration | 2 | 2017 | 103 | 0.070 |
Why?
| | Androstadienes | 1 | 2007 | 107 | 0.070 |
Why?
| | DNA, Complementary | 1 | 2007 | 272 | 0.070 |
Why?
| | Gait | 1 | 2009 | 296 | 0.060 |
Why?
| | Receptors, GABA-A | 1 | 2008 | 142 | 0.060 |
Why?
| | Translocation, Genetic | 1 | 2007 | 105 | 0.060 |
Why?
| | Aeromonas | 1 | 2006 | 1 | 0.060 |
Why?
| | Cytokines | 3 | 2019 | 2085 | 0.060 |
Why?
| | Models, Structural | 1 | 2006 | 40 | 0.060 |
Why?
| | Phosphatidylcholines | 2 | 2017 | 147 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2007 | 226 | 0.060 |
Why?
| | Lung | 1 | 2019 | 4060 | 0.060 |
Why?
| | Corticosterone | 1 | 2007 | 236 | 0.060 |
Why?
| | Muscle Contraction | 1 | 2009 | 424 | 0.060 |
Why?
| | Spectrophotometry, Infrared | 1 | 2006 | 54 | 0.060 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2006 | 21 | 0.060 |
Why?
| | Receptor, Muscarinic M2 | 1 | 2006 | 9 | 0.060 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 1 | 2006 | 29 | 0.060 |
Why?
| | Receptors, Presynaptic | 1 | 2006 | 10 | 0.060 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 145 | 0.060 |
Why?
| | Biological Transport | 1 | 2007 | 418 | 0.060 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 131 | 0.060 |
Why?
| | Receptors, Glutamate | 1 | 2006 | 25 | 0.060 |
Why?
| | Hydrogen | 1 | 2006 | 70 | 0.060 |
Why?
| | Hydroxy Acids | 1 | 2005 | 4 | 0.060 |
Why?
| | Sulfonylurea Receptors | 1 | 2005 | 5 | 0.060 |
Why?
| | Smad Proteins | 1 | 2006 | 42 | 0.060 |
Why?
| | Receptors, Drug | 1 | 2005 | 14 | 0.060 |
Why?
| | Sex Factors | 2 | 2013 | 2071 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 560 | 0.060 |
Why?
| | Decanoic Acids | 1 | 2005 | 8 | 0.060 |
Why?
| | Organic Chemicals | 1 | 2007 | 124 | 0.060 |
Why?
| | Ligands | 1 | 2008 | 664 | 0.060 |
Why?
| | Mass Spectrometry | 2 | 2020 | 739 | 0.060 |
Why?
| | Spleen | 1 | 2007 | 514 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2007 | 267 | 0.060 |
Why?
| | Isoenzymes | 2 | 2005 | 304 | 0.060 |
Why?
| | Hemiplegia | 1 | 2005 | 21 | 0.060 |
Why?
| | Cardiography, Impedance | 1 | 2004 | 8 | 0.060 |
Why?
| | Lower Extremity | 2 | 2009 | 427 | 0.060 |
Why?
| | Treatment Outcome | 6 | 2023 | 10811 | 0.060 |
Why?
| | Ventricular Pressure | 2 | 2016 | 48 | 0.060 |
Why?
| | Imidazoles | 1 | 2006 | 238 | 0.060 |
Why?
| | Young Adult | 3 | 2019 | 13209 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 363 | 0.060 |
Why?
| | Cholinergic Agonists | 1 | 2004 | 6 | 0.060 |
Why?
| | Receptors, Purinergic P2X4 | 1 | 2004 | 6 | 0.060 |
Why?
| | Carbachol | 1 | 2004 | 20 | 0.060 |
Why?
| | Cell Line | 1 | 2010 | 2847 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 476 | 0.060 |
Why?
| | Colforsin | 1 | 2004 | 53 | 0.060 |
Why?
| | Physical Fitness | 1 | 2006 | 209 | 0.060 |
Why?
| | Cardiomegaly | 1 | 2006 | 175 | 0.060 |
Why?
| | Spinal Cord | 1 | 2007 | 370 | 0.060 |
Why?
| | Electric Impedance | 1 | 2004 | 107 | 0.060 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2004 | 89 | 0.050 |
Why?
| | Extracellular Space | 1 | 2004 | 119 | 0.050 |
Why?
| | Blotting, Western | 2 | 2003 | 1226 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2011 | 7635 | 0.050 |
Why?
| | Weight-Bearing | 1 | 2005 | 173 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2008 | 771 | 0.050 |
Why?
| | Merozoite Surface Protein 1 | 1 | 2023 | 4 | 0.050 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 136 | 0.050 |
Why?
| | Autografts | 1 | 2023 | 44 | 0.050 |
Why?
| | Drug Synergism | 1 | 2004 | 382 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2024 | 200 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2023 | 87 | 0.050 |
Why?
| | Models, Statistical | 1 | 2007 | 669 | 0.050 |
Why?
| | Anura | 1 | 2003 | 46 | 0.050 |
Why?
| | Epinephrine | 1 | 2023 | 139 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2023 | 238 | 0.050 |
Why?
| | Receptor, Muscarinic M1 | 1 | 2002 | 3 | 0.050 |
Why?
| | Hyperalgesia | 1 | 2003 | 123 | 0.050 |
Why?
| | Oocytes | 1 | 2003 | 181 | 0.050 |
Why?
| | Australia | 1 | 2023 | 315 | 0.050 |
Why?
| | Phospholipase C beta | 1 | 2002 | 29 | 0.050 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2002 | 28 | 0.050 |
Why?
| | TRPC Cation Channels | 1 | 2002 | 14 | 0.050 |
Why?
| | Heart Ventricles | 1 | 2007 | 788 | 0.050 |
Why?
| | Diglycerides | 1 | 2002 | 61 | 0.050 |
Why?
| | Tibia | 1 | 2003 | 178 | 0.050 |
Why?
| | Calmodulin | 1 | 2002 | 76 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2006 | 778 | 0.050 |
Why?
| | Glycopeptides | 1 | 2002 | 43 | 0.050 |
Why?
| | Hippocampus | 1 | 2007 | 895 | 0.050 |
Why?
| | Glucose | 2 | 2017 | 1020 | 0.040 |
Why?
| | Succinates | 1 | 2021 | 22 | 0.040 |
Why?
| | Fatigue | 1 | 2023 | 329 | 0.040 |
Why?
| | Myocardial Reperfusion | 1 | 2021 | 50 | 0.040 |
Why?
| | Pain Measurement | 1 | 2003 | 521 | 0.040 |
Why?
| | Models, Molecular | 1 | 2006 | 1570 | 0.040 |
Why?
| | Linezolid | 1 | 2020 | 23 | 0.040 |
Why?
| | Cytoskeleton | 1 | 2002 | 191 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2005 | 956 | 0.040 |
Why?
| | Reperfusion | 1 | 2020 | 40 | 0.040 |
Why?
| | Wound Healing | 1 | 2023 | 331 | 0.040 |
Why?
| | Biosensing Techniques | 1 | 2002 | 129 | 0.040 |
Why?
| | Hydrogels | 1 | 2007 | 678 | 0.040 |
Why?
| | Indoles | 1 | 2003 | 412 | 0.040 |
Why?
| | Toxicity Tests | 1 | 2020 | 37 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 219 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2003 | 434 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2019 | 122 | 0.040 |
Why?
| | Actins | 1 | 2002 | 416 | 0.040 |
Why?
| | Ventricular Remodeling | 2 | 2015 | 266 | 0.040 |
Why?
| | Pyridines | 1 | 2003 | 506 | 0.040 |
Why?
| | CA3 Region, Hippocampal | 1 | 2019 | 7 | 0.040 |
Why?
| | Photogrammetry | 1 | 2019 | 6 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2019 | 224 | 0.040 |
Why?
| | Internationality | 1 | 2020 | 155 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2003 | 752 | 0.040 |
Why?
| | Computer-Aided Design | 1 | 2019 | 43 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2019 | 41 | 0.040 |
Why?
| | Drug Design | 1 | 2020 | 167 | 0.040 |
Why?
| | Coenzyme A Ligases | 1 | 2018 | 13 | 0.040 |
Why?
| | Cytochromes c | 1 | 2018 | 60 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1993 | 0.040 |
Why?
| | Delphi Technique | 1 | 2020 | 280 | 0.040 |
Why?
| | Multimodal Imaging | 1 | 2019 | 113 | 0.040 |
Why?
| | Lysophospholipids | 1 | 2018 | 80 | 0.040 |
Why?
| | Biomimetic Materials | 1 | 2018 | 72 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 600 | 0.030 |
Why?
| | Eicosapentaenoic Acid | 1 | 2017 | 39 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2018 | 327 | 0.030 |
Why?
| | Melanocytes | 1 | 2017 | 65 | 0.030 |
Why?
| | Electron Transport Complex III | 1 | 2017 | 16 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2017 | 99 | 0.030 |
Why?
| | Societies, Medical | 1 | 2021 | 820 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2017 | 171 | 0.030 |
Why?
| | Acyltransferases | 1 | 2017 | 57 | 0.030 |
Why?
| | Physical Endurance | 2 | 2009 | 275 | 0.030 |
Why?
| | Epidermis | 1 | 2017 | 157 | 0.030 |
Why?
| | Enzymes | 1 | 2017 | 67 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 683 | 0.030 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1774 | 0.030 |
Why?
| | Neuronal Plasticity | 1 | 2019 | 290 | 0.030 |
Why?
| | Blood Pressure | 1 | 2003 | 1786 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 394 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 193 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2003 | 1276 | 0.030 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2015 | 26 | 0.030 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 38 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2009 | 1316 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2015 | 132 | 0.030 |
Why?
| | Brain | 1 | 2007 | 2668 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1381 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 644 | 0.030 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2005 | 89 | 0.030 |
Why?
| | Infusions, Intra-Arterial | 1 | 2013 | 59 | 0.030 |
Why?
| | Thromboxanes | 1 | 2012 | 17 | 0.030 |
Why?
| | Collagen | 1 | 2015 | 452 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 76 | 0.030 |
Why?
| | Aging | 1 | 2003 | 1864 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 77 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 552 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 443 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2012 | 83 | 0.020 |
Why?
| | Organ Size | 1 | 2013 | 477 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2012 | 182 | 0.020 |
Why?
| | Clonazepam | 1 | 2010 | 5 | 0.020 |
Why?
| | Ouabain | 1 | 2010 | 16 | 0.020 |
Why?
| | Thiazepines | 1 | 2010 | 6 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2018 | 1991 | 0.020 |
Why?
| | Eating | 1 | 2013 | 380 | 0.020 |
Why?
| | Isoproterenol | 1 | 2010 | 113 | 0.020 |
Why?
| | NAD | 1 | 2010 | 77 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 652 | 0.020 |
Why?
| | Perfusion | 1 | 2010 | 213 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 519 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2005 | 1738 | 0.020 |
Why?
| | Patient Selection | 1 | 2013 | 696 | 0.020 |
Why?
| | Transcription Factors | 1 | 2017 | 1719 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2691 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2013 | 635 | 0.020 |
Why?
| | California | 1 | 2009 | 431 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4149 | 0.020 |
Why?
| | Zirconium | 1 | 2007 | 8 | 0.020 |
Why?
| | Neoplasms | 1 | 2003 | 2671 | 0.020 |
Why?
| | Rats, Inbred Lew | 1 | 2007 | 114 | 0.020 |
Why?
| | Lead | 1 | 2007 | 64 | 0.020 |
Why?
| | Torque | 1 | 2007 | 84 | 0.020 |
Why?
| | Rats, Inbred SHR | 1 | 2007 | 45 | 0.020 |
Why?
| | Resistance Training | 1 | 2009 | 164 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2007 | 75 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2007 | 282 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 431 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling 3 Protein | 1 | 2006 | 9 | 0.020 |
Why?
| | Research Design | 1 | 2013 | 1139 | 0.020 |
Why?
| | Materials Testing | 1 | 2007 | 356 | 0.020 |
Why?
| | Ventricular Function | 1 | 2006 | 61 | 0.020 |
Why?
| | Neuronal Calcium-Sensor Proteins | 1 | 2005 | 1 | 0.010 |
Why?
| | Oxotremorine | 1 | 2005 | 2 | 0.010 |
Why?
| | Estrenes | 1 | 2005 | 16 | 0.010 |
Why?
| | Phospholipase C delta | 1 | 2005 | 5 | 0.010 |
Why?
| | Pyrrolidinones | 1 | 2005 | 28 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2006 | 307 | 0.010 |
Why?
| | Neuropeptides | 1 | 2005 | 73 | 0.010 |
Why?
| | DNA Primers | 1 | 2006 | 515 | 0.010 |
Why?
| | Muscle Strength | 1 | 2007 | 317 | 0.010 |
Why?
| | Stroke Volume | 1 | 2007 | 612 | 0.010 |
Why?
| | Electric Stimulation | 1 | 2005 | 264 | 0.010 |
Why?
| | United States | 1 | 2021 | 14841 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2005 | 325 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 2005 | 218 | 0.010 |
Why?
| | Rats, Inbred BN | 1 | 2003 | 58 | 0.010 |
Why?
| | Drug Interactions | 1 | 2005 | 410 | 0.010 |
Why?
| | Green Fluorescent Proteins | 1 | 2005 | 390 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2005 | 321 | 0.010 |
Why?
| | Caffeine | 1 | 2003 | 68 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 2003 | 265 | 0.010 |
Why?
| | Echocardiography | 1 | 2006 | 642 | 0.010 |
Why?
| | Pacemaker, Artificial | 1 | 2003 | 119 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2181 | 0.010 |
Why?
| | Databases, Genetic | 1 | 2003 | 237 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1793 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 767 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 658 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1946 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 21513 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1295 | 0.010 |
Why?
| | Prospective Studies | 1 | 2009 | 7604 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1704 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2004 | 3284 | 0.010 |
Why?
| | Prognosis | 1 | 2004 | 4030 | 0.010 |
Why?
|
|
Brown's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|